Volume 4, Issue 4 (November 2017)
IJML 2017, 4(4): 260-267 |
Back to browse issues page
Behnaz Rahmani 
, Hossein Zarei Jaliani * , Akram Astani , Mohammad Hassan Kheirandish , Ahmad Mosaddegh , Abolghasem Asadi Saghandi
, Hossein Zarei Jaliani * , Akram Astani , Mohammad Hassan Kheirandish , Ahmad Mosaddegh , Abolghasem Asadi Saghandi
Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract: (2135 Views)
Background and Aims: Enzybiotics are probably the future line of weapons against drug resistant bacteria. They lyse bacteria with the new mechanisms with few likelihood of generating resistance. LasA, which is secreted from Pseudomonas strains degrades Staphylococcus aureus (S. aureus) cell wall and has the potential to use against drug resistant S. aureus infections.
Materials and Methods: Codon-optimized gene of the mature form of the LasA protein was ordered. The gene was double digested with NcoI and XhoI restriction enzymes and sub-cloned into pET28a(+) digested with the same enzymes. Recombinant construct was introduced into BL21 DE3 cell. Expression of the gene was induced by 0.2 mM isopropyl β-D-1-thiogalactopyranoside and recombinant protein was affinity purified by Ni-NTA mini-column. The staphylolytic activity of the recombinant LasA protein was evaluated on Methicillin-resistant S. aureus (MRSA) by disk diffusion.
Results: Fragment of the LasA gene encoding mature form of the LasA protein was introduced into pET28a(+) expression vector. C-terminal
his-tagged recombinant LasA protein was produced in BL21 DE3 E. coli cells. Over 50% purity has been achieved by affinity purification of the LasA protein from the total cell lysate. The yield of purified protein was 5.4 mg.l-1. Growth of MRSA was completely inhibited by dilutions of recombinant his-tagged LasA.
Conclusions: The present study shows that the mature form of the LasA can be expressed in E. coli BL21 DE3 cells. C-terminal his-tagged form of the mature LasA protein has staphylolytic activity against MRSA and so it can be a promising therapeutic agent.
Materials and Methods: Codon-optimized gene of the mature form of the LasA protein was ordered. The gene was double digested with NcoI and XhoI restriction enzymes and sub-cloned into pET28a(+) digested with the same enzymes. Recombinant construct was introduced into BL21 DE3 cell. Expression of the gene was induced by 0.2 mM isopropyl β-D-1-thiogalactopyranoside and recombinant protein was affinity purified by Ni-NTA mini-column. The staphylolytic activity of the recombinant LasA protein was evaluated on Methicillin-resistant S. aureus (MRSA) by disk diffusion.
Results: Fragment of the LasA gene encoding mature form of the LasA protein was introduced into pET28a(+) expression vector. C-terminal
his-tagged recombinant LasA protein was produced in BL21 DE3 E. coli cells. Over 50% purity has been achieved by affinity purification of the LasA protein from the total cell lysate. The yield of purified protein was 5.4 mg.l-1. Growth of MRSA was completely inhibited by dilutions of recombinant his-tagged LasA.
Conclusions: The present study shows that the mature form of the LasA can be expressed in E. coli BL21 DE3 cells. C-terminal his-tagged form of the mature LasA protein has staphylolytic activity against MRSA and so it can be a promising therapeutic agent.
Type of Study: Research |
Subject:
Genetics/ Biotechnology
Received: 2017/07/20 | Accepted: 2017/12/3 | Published: 2017/12/31
Received: 2017/07/20 | Accepted: 2017/12/3 | Published: 2017/12/31
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |